Incidence and type of recurrent ventricular arrhythmia in patients with arrhythmic mitral valve prolapse and implantable cardioverter defibrillator for secondary prevention
Authors:
- Kinan KneizehKKKinan Kneizeh
- Frederic SacherFSFrederic Sacher
- Francesco NotaristefanoFNFrancesco Notaristefano
- Konstantinos VlachosKVKonstantinos Vlachos
- Geoffroy DitacGDGeoffroy Ditac
- Josselin DuchateauJDJosselin Duchateau
- Freddy Del-Carpio MunozFMFreddy Del-Carpio Munoz
- Krysztof JaworskiKJKrysztof Jaworski
- Bert VandenberkBVBert Vandenberk
- Stefano FigliozziSFStefano Figliozzi
- Lisa M VerheulLVLisa M Verheul
Open Access
- 15 May 2026
- journal article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (6)
Abstract
Aims: Mitral valve prolapse (MVP) is a common valvular disorder associated with ventricular arrhythmias (VAs) in a subgroup of patients, known as arrhythmic MVP (AMVP). Arrhythmic MVP patients with malignant VAs typically receive an implantable cardioverter-defibrillator (ICD) for secondary prevention. However, data regarding the incidence of appropriate ICD therapy and the type of arrhythmia recurrence in this population remain scarce. This study aimed to evaluate the incidence of appropriate ICD therapies and type of arrhythmia recurrence in AMVP patients with an ICD implanted for secondary prevention. Methods and results: A systematic literature search was conducted in PubMed/MEDLINE and EMBASE databases until January 2025. Studies reporting the incidence of appropriate ICD therapy in AMVP patients were included. A total of 9 studies met the inclusion criteria, resulting in 166 AMVP patients with ICDs for secondary prevention. The mean age was 41.8 years, with 55.8% of patients being female. Over a weighted mean follow-up of 4.9 ± 3.1 years, 34.9% [95% confidence interval (CI): 28.1–42.5] of the patients experienced recurrence of VA. The pooled incidence of appropriate ICD therapies during follow-up was 8.1 per 100 person-years (95% CI: 5.6–10.5, I2: 11.7%). Regarding the type of arrhythmic recurrence, the majority of arrhythmias (53.8%, 95% CI: 44.3–63.0%) were in the form of ventricular fibrillation or polymorphic ventricular tachycardia (VT), while the remaining arrhythmias were reported as monomorphic VT. Among 67 ventricular arrhythmic episodes reported in 7 studies with available data, 65 required shock therapy, corresponding to a shock proportion of 97.0% (95% CI: 89.6–99.6%). Conclusion: Arrhythmic MVP patients with ICDs for secondary prevention exhibit a high risk of recurrent arrhythmias, with recurrences in the form of polymorphic VA occurring in more than half of the cases. PROSPERO registration number: CRD42024588610Keywords
Funding Information
- Leducq International Network (ANR-10-IAHU-04)
This publication has 30 references indexed in Scilit:
- Characterizing Sustained Arrhythmias in Patients With Arrhythmic Mitral Valve ProlapseJACC: Clinical Electrophysiology, 2025
- Isoproterenol Testing as a Sensitive Tool to Unmask Arrhythmogenic Susceptibility In Patients With AMVPJACC: Clinical Electrophysiology, 2025
- Mitral valve prolapse in sudden cardiac arrest survivors: Coincidence or causal relationship?Heart Rhythm, 2025
- The Prevalence and Characteristics of Arrhythmic Mitral Valve Prolapse in Patients With Unexplained Cardiac ArrestJACC: Clinical Electrophysiology, 2023
- Effectiveness of the risk stratification proposed by the 2022 European Heart Rhythm Association Expert Consensus statement on arrhythmic mitral valve prolapseAmerican Heart Journal, 2023
- Mitral Annular Substrate and Ventricular Arrhythmias in Arrhythmogenic Mitral Valve Prolapse With Mitral Annular DisjunctionJACC: Clinical Electrophysiology, 2023
- Malignant Bileaflet Mitral Valve Prolapse Syndrome in Patients With Otherwise Idiopathic Out-of-Hospital Cardiac ArrestJACC, 2013
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Life-threatening arrhythmias in the mitral valve prolapse syndromeThe American Journal of Medicine, 1976